Today: 7 February 2026
Subscribe
Browse Category

Investment Analysis News 1 December 2025 - 2 December 2025

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (NYSE: BMY) has suddenly become one of the most eventful big pharma names to watch as of December 1, 2025. A major lawsuit has been allowed to proceed, new cell therapy approvals are landing, hematology data at ASH 2025 is impressive, and investors are reassessing the stock’s value, dividend and medium‑term growth story. Below is a deep dive into today’s key news, current price, latest forecasts and what it all might mean for BMY stock. This article is for information only and is not investment advice. BMY Stock Snapshot on 1 December 2025 In other words: BMY is
2 December 2025
·····
CME Group (CME) Stock: Outage Fallout, Record Volumes and 2026 Price Targets Explained

CME Group (CME) Stock: Outage Fallout, Record Volumes and 2026 Price Targets Explained

Updated December 1, 2025 CME Group Inc. (NASDAQ: CME), the world’s largest derivatives exchange operator, is ending 2025 on a complicated note. On one hand, the company is posting record volumes in key asset classes, rolling out new crypto benchmarks, launching a prediction‑markets app with FanDuel and expanding in the Middle East. On the other, a rare 10‑hour data‑center failure has put its operational resilience and competitive moat under the microscope. Here’s a deep dive into what’s moving CME Group stock today, how analysts are valuing the shares, and what to watch going into 2026. CME Group Stock Today: Price,
2 December 2025
····
KKR Stock Today (December 1, 2025): Earnings Beat, Analyst Targets and Private Credit Stress Test

KKR Stock Today (December 1, 2025): Earnings Beat, Analyst Targets and Private Credit Stress Test

As of Monday, December 1, 2025, KKR & Co. Inc. (NYSE: KKR) is trading around $122 per share, having bounced back from its autumn lows but still sitting roughly 28% below its 52‑week high of $170.40 set in late January. Yahoo Finance+2MarketWatch+2 The alternative asset manager has just delivered a strong Q3 2025 earnings beat, is facing heightened regulatory scrutiny of private credit, and still carries bullish 12‑month price targets from Wall Street. At the same time, technical and algorithmic models are more cautious in the near term, and the stock’s valuation is rich on trailing earnings. Below is a
1 December 2025
···
HCA Healthcare (HCA) Stock on December 1, 2025: Near All‑Time Highs, Upgraded Guidance and What Comes Next

HCA Healthcare (HCA) Stock on December 1, 2025: Near All‑Time Highs, Upgraded Guidance and What Comes Next

Date: December 1, 2025 – NYSE: HCA HCA Healthcare stock snapshot on December 1, 2025 HCA Healthcare, Inc. (NYSE: HCA), the largest for‑profit hospital operator in the United States, continues to trade near record territory as December begins. Barchart’s latest feature on the stock notes that HCA hit an all‑time high of $520 in the prior session and that shares have soared 71.5% year‑to‑date and 56.5% over the past 12 months, handily beating the Health Care Select Sector SPDR ETF (XLV). Barchart.com Technically, HCA has been trading above its 50‑day moving average since January and above its 200‑day moving average
1 December 2025
····
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie Inc. (NYSE: ABBV) heads into December 2025 as one of the world’s largest healthcare companies, with new migraine data, fresh oncology approvals, a raised 2025 profit forecast and looming U.S. drug‑pricing reforms all shaping sentiment around the stock.The Motley Fool+1 Below is a detailed look at where AbbVie’s stock stands today, what has changed since late November, and how Wall Street now frames the 2026 outlook. AbbVie stock today: price, performance and valuation As of the December 1, 2025 close, AbbVie shares trade at around $225 per share, giving the company a market capitalization near $400 billion.StockAnalysis+1 Key snapshot
1 December 2025
·····
Broadcom Stock After the Bell: AVGO Pulls Back From Highs Even as Wall Street Lifts AI-Driven Price Targets

Broadcom Stock After the Bell: AVGO Pulls Back From Highs Even as Wall Street Lifts AI-Driven Price Targets

Broadcom stock (NASDAQ: AVGO) cooled off on Monday, December 1, 2025, giving back part of its recent AI-fueled rally even as major Wall Street firms raised their price targets and doubled down on the long-term story. After a torrid run that pushed AVGO to fresh 52‑week highs near $403 last week, shares ended Monday’s regular session around $386, roughly 4% below Friday’s close of $402.96 and a short step down from record territory. StockAnalysis+1 So what happened to Broadcom stock after the closing bell on December 1, and how are analysts now framing the AI and VMware story into 2026?
1 December 2025
····
Palantir Stock After the Bell: PLTR Slips as AI Bubble Fears Collide With Explosive Growth (Dec. 1, 2025)

Palantir Stock After the Bell: PLTR Slips as AI Bubble Fears Collide With Explosive Growth (Dec. 1, 2025)

Palantir Technologies’ stock closed slightly lower on Monday, capping off its worst month in two years even as analysts keep ratcheting up earnings forecasts and the company leans into some of the biggest artificial intelligence and defense contracts on the planet. As of Monday’s close, Palantir (NYSE: PLTR) finished around $167.5 per share, down about 0.6% on the day, with after-hours trading showing only marginal additional weakness near $167. Trading volume, roughly 27 million shares, came in well below its recent frenzied average. Investing.com+1 The modest decline looks tame next to November’s damage: Palantir shares fell roughly 19–20% over the
1 December 2025
····
Oracle Stock After the Bell: ORCL Holds the Line Around $201 as Wall Street Splits on Its AI Supercycle – Dec. 1, 2025

Oracle Stock After the Bell: ORCL Holds the Line Around $201 as Wall Street Splits on Its AI Supercycle – Dec. 1, 2025

Updated: December 1, 2025, 10:00 p.m. ET Oracle stock (NYSE: ORCL) ended December 1, 2025 just above $200 after a brutal 40% pullback from September highs. Here’s how traders, analysts, options markets and new AI forecasts are framing Oracle’s outlook heading into its December earnings report. Oracle stock today: calm close after a violent two‑month reset Oracle shares finished Monday’s regular session just over $200 per share, slipping roughly 0.3–0.4% on the day. Intraday, the stock traded in a relatively tight but choppy range of about $196.7 to $203.5, on volume around 10–11 million shares—roughly in line with recent averages. Investing.com+1 That subdued close comes after
1 December 2025
·····
Apple Stock After the Bell: AAPL Nears $283 as Wall Street Debates Valuation, AI Strategy and the iPhone 17 Boom

Apple Stock After the Bell: AAPL Nears $283 as Wall Street Debates Valuation, AI Strategy and the iPhone 17 Boom

On Monday, December 1, 2025, Apple (NASDAQ: AAPL) wrapped regular trading near $283 per share, up about 1.5% on the day, and held those gains in relatively quiet after‑hours trading. That leaves the stock close to its 52‑week highs and back above the psychologically important $4 trillion market‑cap mark. MarketBeat+2Barchart.com+2 At 10 p.m. EST, investors are digesting a flood of fresh research published today: bullish free‑cash‑flow valuations, bearish technical calls, algorithmic price forecasts and new regulatory and supply‑chain headlines. Here’s how Apple’s story looks after the bell — and what it might mean for AAPL into 2026. Apple stock today: price action and positioning In
1 December 2025
····
Beyond Meat Hit With $38.9M Vegadelphia Verdict as BYND Stock Lures Bullish Options Traders

Beyond Meat Hit With $38.9M Vegadelphia Verdict as BYND Stock Lures Bullish Options Traders

Beyond Meat – which is in the midst of rebranding simply as “Beyond” – is ending 2025 under intense pressure on almost every front: a $38.9 million trademark verdict, a fresh wave of securities‑fraud investigations, deepening operating losses and impairments, and yet another round of meme‑stock speculation and bullish options bets in a stock now trading around $1 per share. GuruFocus+3Food Business MEA+3Reuters+3 Here’s how the latest legal, financial, and market developments fit together as of December 1, 2025. 1. The $38.9 Million Vegadelphia Verdict: How Bad Is It? On November 24, a federal jury in Massachusetts found Beyond Meat
1 December 2025
···
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

On December 1, 2025, Q32 Bio Inc. (NASDAQ: QTTB) suddenly became one of the most-watched small-cap biotech stocks on Wall Street. Shares of Q32 Bio surged intraday by roughly 90%–170% at various points in Monday’s session, with trading volume soaring from a typical few hundred thousand shares to tens or even hundreds of millions, after the company announced a major asset sale to Akebia Therapeutics. TipRanks+224/7 MarketNews+2 At the center of the move: the sale of Q32 Bio’s Phase 2 complement inhibitor ADX-097 to Akebia in a deal worth $12 million in upfront and near-term cash and up to $592
1 December 2025
······
Cisco Stock on December 1, 2025: AI Momentum, Quantum Networking and Wall Street’s Latest CSCO Forecasts

Cisco Stock on December 1, 2025: AI Momentum, Quantum Networking and Wall Street’s Latest CSCO Forecasts

Published: December 1, 2025 – Information only, not investment advice. Snapshot: Where Cisco Stock Stands Today As of intraday trading on December 1, 2025, Cisco Systems, Inc. (NASDAQ: CSCO) is changing hands at around $76–77 per share, with a recent quote near $76.30 and an intraday range of roughly $76.04–$76.87.MarketBeat At this level: From a longer-term lens, Cisco’s 2025 rally has been dramatic enough that the stock is finally trading back above the level of its famous 2000-era “you’ve got to own Cisco” magazine cover, though still just shy of its dot-com peak near $80.The Big Picture That context underscores
1 December 2025
···
1 … 229 230 231 232 233 … 282

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop